UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals
Posted on January 09, 2013 at 12:44 PM EST
In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR ), and raised its price target from $27.00 to $36.00. Canaccord Genuity noted, “AEGR announced additional Juxtapid launch color, with the key takeaways being the $235K/$295K U.S. annual pricing (vs. our $250K estimate) for